McKesson Eyes $5B Option Care Health Deal With CD&R

A major healthcare deal is taking shape. McKesson and private equity heavyweight Clayton, Dubilier & Rice are in discussions to acquire Option Care Health in a transaction valued at roughly $5 billion, according to reporting from the Financial Times. If it closes, this would be one of the more significant healthcare distribution plays in recent memory.

Option Care Health is the largest independent provider of home and alternate-site infusion services in the United States. That makes it a genuinely attractive target — home infusion is a high-growth space as payers and patients push care out of expensive hospital settings and into lower-cost alternatives. McKesson already has deep roots in pharmaceutical distribution, so adding Option Care's infusion network would be a logical vertical extension of its core business.

Read more Nvidia, Alphabet, Meta Sign AI Safety Accord; Microsoft Holds Back →

For CD&R, this fits the firm's well-established playbook of partnering with strategic buyers on healthcare carve-outs and platform acquisitions. The private equity angle here suggests the final structure could involve a split or co-ownership arrangement rather than a straightforward outright acquisition — worth watching as terms get finalized.

For traders, Option Care Health shares are the obvious immediate focus. A confirmed $5 billion deal would put a hard floor under the stock and likely compress any remaining discount to deal price fast. McKesson shareholders will want to scrutinize how the company plans to finance the transaction and whether leverage assumptions hold up under current rate conditions. Talks are ongoing and no deal has been finalized, so headline risk cuts both ways until a signed agreement lands.

Continue reading at SeekingAlpha.